{"id":929473,"date":"2019-11-11T11:34:38","date_gmt":"2019-11-11T10:34:38","guid":{"rendered":"https:\/\/frezzapartners.com\/?p=929473"},"modified":"2019-11-11T14:44:52","modified_gmt":"2019-11-11T13:44:52","slug":"929473","status":"publish","type":"post","link":"https:\/\/frezzapartners.com\/en\/929473\/","title":{"rendered":"Accordo Biogen-Samsung Bioepis per commercializzazione biosimilari"},"content":{"rendered":"<p>photo by <span class=\"attribution_field hide-sm hide-md\">mohamed Hassan<\/span><\/p>\n<p>&nbsp;<\/p>\n<p>Biogen ha annunciato ufficilamente la proposta di un accordo con Samsung Bioepis. Obiettivo sarebbe quello di ottenere l&#8217;esclusiva per la commercializzazione di due nuovi biosimilari, SB11 e SB15 (ranibizumab e afliber-cept) negli Stati Uniti, in Canada, Europa, Giappone e Australia. Inoltre, Biogen acquisir\u00e0 l&#8217;esclusiva per la commercializzazione di etanercept, infliximab e adalimumab nel mercato cinese. L&#8217;azienda potr\u00e0 inoltre estendere il termine del suo accordo commerciale con Samsung Bioepis per il suo portafoglio di farmaci anti-Tnf in Europa. In base ai termini proposti, Biogen dovr\u00e0 inizialmente corrispondere a Samsung Bioepis circa 100 milioni di dollari. In pi\u00f9, potrebbe corrispondere fino a 210 milioni di dollari in base al raggiungimento di obiettivi di sviluppo, approvazioni regolatorie e volumi di vendite. Samsung Bioepis avr\u00e0 la responsabilit\u00e0 dello sviluppo e fornir\u00e0 entrambi i prodotti a Biogen con un margine lordo prefissato. Biogen potr\u00e0 estendere il suo accordo commerciale gi\u00e0 in essere in Europa per i suoi tre biosimilari anti-Tnf (per ulteriori 5 anni ), previo pagamento di un diritto di opzione di 60 milioni di dollari.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>photo by mohamed Hassan &nbsp; Biogen ha annunciato ufficilamente la proposta di un accordo con Samsung Bioepis. Obiettivo sarebbe quello di ottenere l&#8217;esclusiva per la commercializzazione di due nuovi biosimilari, SB11 e SB15 (ranibizumab e afliber-cept) negli Stati Uniti, in Canada, Europa, Giappone e Australia. Inoltre, Biogen acquisir\u00e0 l&#8217;esclusiva per la commercializzazione di etanercept, infliximab e adalimumab nel mercato cinese. L&#8217;azienda potr\u00e0 inoltre estendere il termine del suo accordo commerciale con Samsung Bioepis per il suo portafoglio di farmaci anti-Tnf&#8230;<\/p>\n","protected":false},"author":297440,"featured_media":929476,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[141],"tags":[],"class_list":["post-929473","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Accordo Biogen-Samsung Bioepis per commercializzazione biosimilari - Frezza Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/frezzapartners.com\/929473\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accordo Biogen-Samsung Bioepis per commercializzazione biosimilari - Frezza Partners\" \/>\n<meta property=\"og:description\" content=\"photo by mohamed Hassan &nbsp; Biogen ha annunciato ufficilamente la proposta di un accordo con Samsung Bioepis. Obiettivo sarebbe quello di ottenere l&#8217;esclusiva per la commercializzazione di due nuovi biosimilari, SB11 e SB15 (ranibizumab e afliber-cept) negli Stati Uniti, in Canada, Europa, Giappone e Australia. Inoltre, Biogen acquisir\u00e0 l&#8217;esclusiva per la commercializzazione di etanercept, infliximab e adalimumab nel mercato cinese. L&#8217;azienda potr\u00e0 inoltre estendere il termine del suo accordo commerciale con Samsung Bioepis per il suo portafoglio di farmaci anti-Tnf...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/frezzapartners.com\/929473\/\" \/>\n<meta property=\"og:site_name\" content=\"Frezza Partners\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-11T10:34:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-11-11T13:44:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/frezzapartners.com\/wp-content\/uploads\/2019\/11\/contract-4085336_1920.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1238\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frezza Partners\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frezza Partners\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/929473\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/929473\\\/\"},\"author\":{\"name\":\"Frezza Partners\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"headline\":\"Accordo Biogen-Samsung Bioepis per commercializzazione biosimilari\",\"datePublished\":\"2019-11-11T10:34:38+00:00\",\"dateModified\":\"2019-11-11T13:44:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/929473\\\/\"},\"wordCount\":181,\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/929473\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/contract-4085336_1920.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/929473\\\/\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/929473\\\/\",\"name\":\"Accordo Biogen-Samsung Bioepis per commercializzazione biosimilari - Frezza Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/929473\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/929473\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/contract-4085336_1920.jpg\",\"datePublished\":\"2019-11-11T10:34:38+00:00\",\"dateModified\":\"2019-11-11T13:44:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/929473\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/frezzapartners.com\\\/929473\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/929473\\\/#primaryimage\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/contract-4085336_1920.jpg\",\"contentUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/contract-4085336_1920.jpg\",\"width\":1920,\"height\":1238},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/929473\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/frezzapartners.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accordo Biogen-Samsung Bioepis per commercializzazione biosimilari\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/\",\"name\":\"Frezza Partners\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/frezzapartners.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\",\"name\":\"Frezza Partners\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/en\\\/author\\\/fr3zz4partn3rs\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accordo Biogen-Samsung Bioepis per commercializzazione biosimilari - Frezza Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/frezzapartners.com\/929473\/","og_locale":"en_US","og_type":"article","og_title":"Accordo Biogen-Samsung Bioepis per commercializzazione biosimilari - Frezza Partners","og_description":"photo by mohamed Hassan &nbsp; Biogen ha annunciato ufficilamente la proposta di un accordo con Samsung Bioepis. Obiettivo sarebbe quello di ottenere l&#8217;esclusiva per la commercializzazione di due nuovi biosimilari, SB11 e SB15 (ranibizumab e afliber-cept) negli Stati Uniti, in Canada, Europa, Giappone e Australia. Inoltre, Biogen acquisir\u00e0 l&#8217;esclusiva per la commercializzazione di etanercept, infliximab e adalimumab nel mercato cinese. L&#8217;azienda potr\u00e0 inoltre estendere il termine del suo accordo commerciale con Samsung Bioepis per il suo portafoglio di farmaci anti-Tnf...","og_url":"https:\/\/frezzapartners.com\/929473\/","og_site_name":"Frezza Partners","article_published_time":"2019-11-11T10:34:38+00:00","article_modified_time":"2019-11-11T13:44:52+00:00","og_image":[{"width":1920,"height":1238,"url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2019\/11\/contract-4085336_1920.jpg","type":"image\/jpeg"}],"author":"Frezza Partners","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Frezza Partners","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/frezzapartners.com\/929473\/#article","isPartOf":{"@id":"https:\/\/frezzapartners.com\/929473\/"},"author":{"name":"Frezza Partners","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"headline":"Accordo Biogen-Samsung Bioepis per commercializzazione biosimilari","datePublished":"2019-11-11T10:34:38+00:00","dateModified":"2019-11-11T13:44:52+00:00","mainEntityOfPage":{"@id":"https:\/\/frezzapartners.com\/929473\/"},"wordCount":181,"image":{"@id":"https:\/\/frezzapartners.com\/929473\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2019\/11\/contract-4085336_1920.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/frezzapartners.com\/929473\/","url":"https:\/\/frezzapartners.com\/929473\/","name":"Accordo Biogen-Samsung Bioepis per commercializzazione biosimilari - Frezza Partners","isPartOf":{"@id":"https:\/\/frezzapartners.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/frezzapartners.com\/929473\/#primaryimage"},"image":{"@id":"https:\/\/frezzapartners.com\/929473\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2019\/11\/contract-4085336_1920.jpg","datePublished":"2019-11-11T10:34:38+00:00","dateModified":"2019-11-11T13:44:52+00:00","author":{"@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"breadcrumb":{"@id":"https:\/\/frezzapartners.com\/929473\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/frezzapartners.com\/929473\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/frezzapartners.com\/929473\/#primaryimage","url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2019\/11\/contract-4085336_1920.jpg","contentUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2019\/11\/contract-4085336_1920.jpg","width":1920,"height":1238},{"@type":"BreadcrumbList","@id":"https:\/\/frezzapartners.com\/929473\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/frezzapartners.com\/"},{"@type":"ListItem","position":2,"name":"Accordo Biogen-Samsung Bioepis per commercializzazione biosimilari"}]},{"@type":"WebSite","@id":"https:\/\/frezzapartners.com\/#website","url":"https:\/\/frezzapartners.com\/","name":"Frezza Partners","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/frezzapartners.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0","name":"Frezza Partners","url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/"}]}},"_links":{"self":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/929473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/users\/297440"}],"replies":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/comments?post=929473"}],"version-history":[{"count":0,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/929473\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media\/929476"}],"wp:attachment":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media?parent=929473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/categories?post=929473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/tags?post=929473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}